Background: Prasugrel is a novel third-generation thienopyridine P2Y12 receptor antagonist with more rapid, potent, and consistent platelet inhibition than clopidogrel. [23] Aim: Compare the ...

For patients with ACS undergoing DES implantation, de-escalating DAPT to P2Y12 inhibitor monotherapy is associated with lower bleeding risk.

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...

Dual antiplatelet therapy with aspirin plus an oral P2Y12 inhibitor is still indicated for at least 12 months for patients with ACS who are not at high risk for bleeding, and ticagrelor (Brilinta ...

New Delhi: Mylan Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome. HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with ...